Amylyx Pharmaceuticals, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

AMLX$30.91+2.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
Shares · Amount · Capital · Income (Loss) · Deficit · Equity
Balance as of December 31, 2024	68,629,738	$7	$771,542	$(92)	$(606,692)		$164,765
Issuance of common stock upon financing, net of issuance costs	19,714,285	2	65,575	—	—		65,577
Issuance of common stock upon exercise of stock options	36,310	—	57	—	—		57
Issuance of common stock upon vesting of RSUs	700,488	—	—	—	—		—
Stock-based compensation expense	—	—	6,833	—	—		6,833
Other comprehensive income	—	—	—	92	—		92
Net loss	—	—	—	—	(35,907)		(35,907)
Balance as of March 31, 2025	89,080,821	$9	$844,007	$—	$(642,599)		$201,417
Issuance of common stock upon exercise of stock options	855	—	2	—	—		2
Issuance of common stock upon vesting of RSUs	74,674	—	—	—	—		—
Stock-based compensation expense	—	—	7,350	—	—		7,350
Other comprehensive income	—	—	—	551	—		551
Net loss	—	—	—	—	(41,443)		(41,443)
Balance as of June 30, 2025	89,156,350	$9	$851,359	$551	$(684,042)		$167,877
Issuance of common stock upon financing, net of issuance costs	20,125,000	2	$190,735			190,737
Issuance of common stock upon exercise of stock options	95,787	—	428	—	—		428
Issuance of common stock upon vesting of RSUs	389,245	—	—	—	—		—
Stock-based compensation expense	—	—	7,076	—	—		7,076
Other comprehensive income	—	—	—	264	—		264
Net loss	—	—	—	—	(34,386)		(34,386)
Balance as of September 30, 2025	109,766,382	$11	$1,049,598	$815	$(718,428)		$331,996

Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance as of December 31, 2023	67,707,432	$7	$738,177	$197	$(304,949)	$433,432
Issuance of common stock upon exercise of stock options	49,618	—	147	—	—	147
Issuance of common stock upon vesting of RSUs	218,537	—	—	—	—	—
Stock-based compensation expense	—	—	9,924	—	—	9,924
Other comprehensive loss	—	—	—	(274)	—	(274)
Net loss	—	—	—	—	(118,793)	(118,793)
Balance as of March 31, 2024	67,975,587	$7	$748,248	$(77)	$(423,742)	$324,436
Issuance of common stock upon exercise of stock options	59,981	—	23	—	—	23
Issuance of common stock upon vesting of RSUs	43,489	—	—	—	—	—
Stock-based compensation expense	—	—	9,570	—	—	9,570
Other comprehensive loss	—	—	—	(20)	—	(20)
Net loss	—	—	—	—	(72,700)	(72,700)
Balance as of June 30, 2024	68,079,057	$7	$757,841	$(97)	$(496,442)	$261,309
Issuance of common stock upon exercise of stock options	36,799	—	57	—	—	57
Issuance of common stock upon vesting of RSUs	429,652	—	—	—	—	—
Stock-based compensation expense	—	—	6,803	—	—	6,803
Other comprehensive income	—	—	—	738	—	738
Net loss	—	—	—	—	(72,704)	(72,704)
Balance as of September 30, 2024	68,545,508	$7	$764,701	$641	$(569,146)	$196,203

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.